Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $12.20 $16.47 Friday, 10th May 2024 VRDN stock ended at $13.90. This is 0.0719% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 5.32% from a day low at $13.34 to a day high of $14.05.
90 days $12.20 $21.42
52 weeks $10.93 $28.35

Historical Viridian Therapeutics, Inc. prices

Date Open High Low Close Volume
Aug 30, 2023 $18.50 $18.72 $18.12 $18.51 445 732
Aug 29, 2023 $18.61 $18.86 $18.24 $18.44 294 265
Aug 28, 2023 $18.76 $18.95 $18.34 $18.60 415 205
Aug 25, 2023 $18.81 $18.99 $18.28 $18.68 421 708
Aug 24, 2023 $18.98 $19.03 $18.34 $18.80 720 083
Aug 23, 2023 $19.71 $19.85 $18.96 $19.00 240 739
Aug 22, 2023 $19.90 $20.05 $19.49 $19.62 230 798
Aug 21, 2023 $19.45 $20.47 $19.18 $19.89 423 641
Aug 18, 2023 $18.79 $19.56 $18.74 $19.45 306 289
Aug 17, 2023 $19.39 $19.50 $18.92 $19.04 304 370
Aug 16, 2023 $19.52 $19.76 $19.17 $19.44 340 865
Aug 15, 2023 $19.81 $20.14 $19.51 $19.56 506 910
Aug 14, 2023 $19.32 $19.90 $19.27 $19.81 544 608
Aug 11, 2023 $19.52 $19.85 $19.26 $19.62 278 178
Aug 10, 2023 $19.30 $19.68 $19.03 $19.52 467 008
Aug 09, 2023 $18.79 $19.91 $18.73 $19.26 849 015
Aug 08, 2023 $17.80 $18.78 $17.69 $18.75 1 068 431
Aug 07, 2023 $18.61 $18.61 $17.49 $17.74 987 000
Aug 04, 2023 $18.23 $18.76 $17.91 $18.57 485 231
Aug 03, 2023 $18.18 $18.27 $17.85 $18.10 571 163
Aug 02, 2023 $18.45 $18.60 $18.17 $18.36 500 040
Aug 01, 2023 $18.74 $18.88 $18.40 $18.65 500 365
Jul 31, 2023 $18.68 $18.96 $18.42 $18.76 296 898
Jul 28, 2023 $18.40 $19.26 $18.21 $18.72 682 058
Jul 27, 2023 $18.87 $19.01 $18.05 $18.18 907 861
Click to get the best stock tips daily for free!

About Viridian Therapeutics, Inc.

Viridian Therapeutics. Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as ... VRDN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT